Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
Public ClinicalTrials.gov record NCT00630331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
Study identification
- NCT ID
- NCT00630331
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 11,404 participants
Conditions and interventions
Conditions
Interventions
- Cell culture-derived influenza vaccine Biological
- Egg-derived influenza virus vaccine Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 49 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2007 (Type not available)
- Primary completion
- Jul 2008 (Actual)
- Completion
- Jul 2008 (Actual)
- Last update posted
- May 24, 2024
2007 – 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 14 | Denver | Colorado | 80212 | — |
| Site 15 | Pembroke Pines | Florida | 33024 | — |
| Site 17 | South Miami | Florida | 33143 | — |
| Site 13 | Lenexa | Kansas | 66219 | — |
| Site 2 | Bardstown | Kentucky | 40004 | — |
| Site 1 | St Louis | Missouri | 63140 | — |
| Site 4 | Edison | New Jersey | 08817 | — |
| Site 10 | Binghamton | New York | 13901 | — |
| Site 5 | Endwell | New York | 13760 | — |
| Site 16 | Winston-Salem | North Carolina | 27103 | — |
| Site 11 | Warwick | Rhode Island | 02886 | — |
| Site 12 | Anderson | South Carolina | 29621 | — |
| Site 9 | Austin | Texas | 78705 | — |
| Site 8 | Dallas | Texas | 75234 | — |
| Site 7 | Salt Lake City | Utah | 84109 | — |
| Site 3 | Salt Lake City | Utah | 84121 | — |
| Site 6 | Burke | Virginia | 22105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00630331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 24, 2024 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00630331 live on ClinicalTrials.gov.